PureTech Health (PRTC) Competitors

Genus (LON:GNS) and PureTech Health (LON:PRTC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, community ranking, dividends, analyst recommendations, institutional ownership and media sentiment.

Do analysts recommend GNS or PRTC?

Genus presently has a consensus target price of GBX 2,150, suggesting a potential upside of 4.88%. PureTech Health has a consensus target price of GBX 455, suggesting a potential upside of 240.06%. Given PureTech Health's higher possible upside, analysts clearly believe PureTech Health is more favorable than Genus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genus	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more volatility and risk, GNS or PRTC?

Genus has a beta of 0.37, indicating that its stock price is 63% less volatile than the S&P 500. Comparatively, PureTech Health has a beta of 1.02, indicating that its stock price is 2% more volatile than the S&P 500.

Do institutionals & insiders have more ownership in GNS or PRTC?

77.8% of Genus shares are held by institutional investors. Comparatively, 79.9% of PureTech Health shares are held by institutional investors. 0.8% of Genus shares are held by company insiders. Comparatively, 15.9% of PureTech Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Which has stronger earnings and valuation, GNS or PRTC?

Genus has higher revenue and earnings than PureTech Health. PureTech Health is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genus	£666.67M	2.01	£7.87M	£12.06	169.93
PureTech Health	£521.32K	770.95	-£91.86M	-£24.38	-5.49

Does the MarketBeat Community prefer GNS or PRTC?

PureTech Health received 177 more outperform votes than Genus when rated by MarketBeat users. Likewise, 86.60% of users gave PureTech Health an outperform vote while only 70.60% of users gave Genus an outperform vote.

Company	Underperform	Outperform
Genus	Outperform Votes 353 70.60%	Underperform Votes 147 29.40%
PureTech Health	Outperform Votes 530 86.60%	Underperform Votes 82 13.40%

Is GNS or PRTC more profitable?

Genus has a net margin of 1.18% compared to PureTech Health's net margin of -17,620.94%. Genus' return on equity of 1.41% beat PureTech Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genus	1.18%	1.41%	3.31%
PureTech Health	-17,620.94%	-21.15%	-13.39%

Does the media favor GNS or PRTC?

In the previous week, Genus and Genus both had 1 articles in the media. Genus' average media sentiment score of 0.55 beat PureTech Health's score of 0.00 indicating that Genus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genus	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PureTech Health	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Genus beats PureTech Health on 9 of the 16 factors compared between the two stocks.